# Zyomyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zyomyx

- Industry: Biotechnology
- Headquarters: Fremont, US
- Website: www.zyomyx.com
- Total disclosed funding: $104M
- Latest round: Series B (Jun 30, 2013)
- Investors on record: 23

## About

Zyomyx, Inc is an innovator in the development and commercialization of proprietary diagnostic platforms.

## Funding rounds

- Series B, Jun 30, 2013, $12M — Alloy Ventures, Mylan N.V., Bill and Melinda Gates Foundation
- Series F, Feb 12, 2004, $10M — Alloy Ventures, GCM Grosvenor, Mediphase Venture Partners, Lilly Ventures, Credit Suisse, Tekla Capital Management, SG Growth Capital, Hambrecht & Quist, Biomedical Sciences Investment Fund
- Series E, Jul 22, 2002, $27M — Lilly Ventures, Credit Suisse, GE Capital
- Series D, Dec 4, 2000, $33M — Alloy Ventures, Mediphase Venture Partners, Skyline Ventures, Sumitomo Corporation, Yasuda Enterprise Development, Invus [DUP], Credit Suisse, China Development Bank Capital, SoftBank Group, MSDW Venture Partners
- Series C, Mar 31, 2000, $22M — Alloy Ventures, Burrill & Company, Mediphase Venture Partners, Skyline Ventures, Tekla Capital Management, Lombard Odier Asset Management, Singapore Bio-Innovations
- Series B, Mar 31, 1999 — Skyline Ventures, Lombard Odier Asset Management, Asset Management, Hambrecht & Quist
- Series A, Jan 1, 1998 — Skyline Ventures

## Investors

- Skyline Ventures (https://capitalatlas.ai/funds/skyline-ventures) — Series A, Series B, Series C, Series D
- Lombard Odier Asset Management — Series B, Series C
- Asset Management — Series B
- Hambrecht & Quist (https://capitalatlas.ai/funds/hambrecht-quist) — Series B, Series F
- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series C, Series D, Series F, Series B
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series C
- Mediphase Venture Partners (https://capitalatlas.ai/funds/mediphase-venture-partners) — Series C, Series D, Series F
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series C, Series F
- Singapore Bio-Innovations (https://capitalatlas.ai/funds/singapore-bio-innovations) — Series C
- Sumitomo Corporation — Series D
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series D
- Invus [DUP] — Series D
- Credit Suisse (https://capitalatlas.ai/funds/credit-suisse) — Series D, Series E, Series F
- China Development Bank Capital — Series D
- SoftBank Group — Series D
- MSDW Venture Partners (https://capitalatlas.ai/funds/msdw-venture-partners) — Series D
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series E, Series F
- GE Capital — Series E
- GCM Grosvenor — Series F
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series F
- Biomedical Sciences Investment Fund — Series F
- Mylan N.V. — Series B
- Bill and Melinda Gates Foundation — Series B